ArticlebioRxiv : the preprint server for biology2025
Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer.
Galina Semenova et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.